ClinicalTrials.Veeva

Find clinical trials for Prostate Cancer in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Cancer
Carcinoma
Hypersensitivity
Recurrence
Adenocarcinoma
Breast Cancer

Prostate Cancer trials near New Haven, CT, USA:

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate...

Active, not recruiting
Prostate Cancer
Drug: Placebo oral tablet
Drug: Luteinizing Hormone-Releasing Hormone Analog

Phase 3

University of Sydney

Commack, New York, United States and 92 other locations

pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate...

Enrolling
Castration Resistant Prostatic Cancer
Metastatic Castration-resistant Prostate Cancer
Biological: JANX007

Phase 1

Janux Therapeutics

New Haven, Connecticut, United States and 10 other locations

Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA val...

Active, not recruiting
Prostate Cancer Metastatic
Drug: ARV-110 in Combination with Abiraterone

Phase 1

Arvinas
Arvinas

New Haven, Connecticut, United States and 17 other locations

is a safe and effective way to treat previously untreated metastatic prostate cancer, and to see whether the study treatment works ...

Active, not recruiting
Metastatic Prostate Cancer
Drug: Abiraterone
Drug: Atezolizumab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 7 other locations

A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate...

Enrolling
Prostate Cancer Metastatic
Drug: ARV-766 + Abiraterone Part C&D
Drug: ARV-766 Part A&B

Phase 1, Phase 2

Arvinas
Arvinas

New Haven, Connecticut, United States and 22 other locations

Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic the...

Active, not recruiting
Prostate Cancer Metastatic
Drug: ARV-110

Phase 1, Phase 2

Arvinas
Arvinas

New Haven, Connecticut, United States and 53 other locations

Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...

Enrolling
Prostate Cancer
Drug: Enzalutamide
Drug: AMG 509

Phase 1

Amgen
Amgen

New Haven, Connecticut, United States and 43 other locations

This study is comparing the safety and effectiveness of abiraterone acetate alone, followed by the addition of prednisone (when the participant's dis...

Active, not recruiting
Castration-resistant Prostate Cancer
Drug: abiraterone acetate

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Commack, New York, United States and 7 other locations

The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer...

Enrolling
Prostate Cancer
Drug: Relugolix 120 MG [Orgovyx]
Radiation: SBRT standard of care radiotherapy treatment

Phase 2

Yale University
Yale University

New Haven, Connecticut, United States

This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate...

Enrolling
Prostate Cancer
Radiation: Radiation Therapy
Drug: Darolutamide

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 11 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems